ProfileGDS5678 / 1420093_s_at
TitleAnti-VEGF and Anti-Notch treatment effect on U87 glioblastoma xenograft tumors [Mouse430_2]
OrganismMus musculus


control bevacizumab dibenzazepine GSM967852 GSM967853 GSM967854 GSM967855 GSM967856 GSM967862 GSM967863 GSM967864 GSM967865 GSM967857 GSM967858 GSM967859 GSM967860 GSM967861 92% 91% 92% 91% 91% 92% 91% 90% 91% 92% 91% 92% 92% 92% sort by agent Gene Expression Profile
Graph caption help
SampleTitleValueRank
GSM967852U87-EV human glioblastoma xenograft - Control 17.4817992
GSM967853U87-EV human glioblastoma xenograft - Control 27.5621691
GSM967854U87-EV human glioblastoma xenograft - Control 37.6055692
GSM967855U87-EV human glioblastoma xenograft - Control 47.5915991
GSM967856U87-EV human glioblastoma xenograft - Control 57.5214891
GSM967862U87-EV human glioblastoma xenograft - Bevacizumab treated 17.447592
GSM967863U87-EV human glioblastoma xenograft - Bevacizumab treated 27.2800191
GSM967864U87-EV human glioblastoma xenograft - Bevacizumab treated 37.236790
GSM967865U87-EV human glioblastoma xenograft - Bevacizumab treated 47.4705591
GSM967857U87-EV human glioblastoma xenograft - dibenzazepine treated 17.5770492
GSM967858U87-EV human glioblastoma xenograft - dibenzazepine treated 27.450891
GSM967859U87-EV human glioblastoma xenograft - dibenzazepine treated 37.6634592
GSM967860U87-EV human glioblastoma xenograft - dibenzazepine treated 47.717792
GSM967861U87-EV human glioblastoma xenograft - dibenzazepine treated 57.5078292